Abstract
The search for tumour specific immune reactions was triggered by the formulation of the immune surveillance hypothesis as early as 1909 [1] and by its later updates [2]. The central idea of immune surveillance is that the immune system has the capacity, not only to distinguish ‘self ’from ‘non-self’, but also to distinguish cancer cells in the body from their normal counterparts. As a result the immune system may arrest or eliminate the cancer cells from the tumour bearing host. The fascination with this concept has initiated and stimulated cancer immunologists to classify tumours on the basis of their antigenic ‘make-up’ and their reaction to cytokines. To this end a wide range of animal species were immunised with (human) tumour cells to raise antisera for the serological dissection of cancer. With the advent of monoclonal antibodies (mAb) an even more precise knowledge was gained about carbohydrate epitopes on the glycoprotein, glycolipid and ganglioside antigen structure of tumour cells [3]. All these efforts have generated serological reagents, that are now widely applied in the laboratory and clinic, ranging from application in fundamental tumour cell biology to the use for immunodiagnosis in the laboratory and in vivo and for immunotherapy.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Ehrlich P. Uber den Jetzigen Stand der Karzinomforschung.Ned Tijdschr Geneeskd 1909; 35: 273–90.
Burnet FM. The concept of immunological surveillance.Progr Exper Tumor Res 1970; 13: 1–27.
Lloyd KO, Old LJ. Human monoclonal antibodies toglycolipids and other carbohydrate antigens.Dissection of the humoral immune response in cancer patients. Cancer Res 1989;49: 3445–51.
Hersey P, Bolhuis RLH. Non-specific MHC-unrestrictedkiller cells and their receptors. Immunol Today 1987; 8: 233–9.
Bolhuis RLHB, Braakman E. Lymphocyte-mediated responses:activation of, and lysis by, cytotoxic lymphocytes. Curr Opin Immunol 1988; 1: 236–40.
Köhler G, Milstein C. Continuous cultures of fused cellssecreting antibody of predefined specificity. Nature 1975; 256: 495–7.
Acuto O, Hussey RE, Fitzgerald KA, et al. The humanT-cell receptor: Appearance in ontogeny and biochemicalrelationship of and ßsubunits on IL-2 dependent clonesand T-cell tumors.Cell 1983; 34: 717–26.
Staertz UD, Pasternack MS, Klein JR, et al. Monoclonalantibodies specific for a murine cytotoxic T-lymphocyte clone. Proc Natl AcadSci USA 1984; 1799–803.
Bolhuis RLH, Gravekamp C, Van de Griend RJ. Cell-Cellinteractions. Clin Immunol Allergy 1986; 6: 29–90.
Lanier L, Ruitenberg JJ, Phillips JH. Human CD3+T lymphocytes that express neither CD4 nor CD8. J Exp Med 1986; 164: 339–44.
FerriniSG, Bottino C, Blassoni R, et al. Characterization of CD3 + , CD4, CD8 clones expressing theputative T-cell receptor gamma gene product. J Exp Med 1987; 166: 277–82.
Borst J, Van de Griend R, Van Oostveen H, et al. AT-cell receptor /CD3 complex found on cloned functional lymphocytes. Nature1987; 325: 683–8.
Brenner MB, McLean J, Scheft H, et al. Two forms of theT-cell receptor gamma protein found on peripheral blood cytotoxic Tlymphocytes. Nature 1987; 325: 689–94.
Van de Griend RJ, Tax WJM, Van Krimpen BA, et al. Lysisof tumor cells by CD3 + ,4-, 8-, 16+ T-cell receptor a/T-clones regulated via CD3 andCD 16 activation sites, recombinant interleukin 2 and interferon ß.JImmunol 1987; 138: 1627–33.
SturmE, Braakman E, Bontrop RE, et al. Coordinated V and V gene-segment rearrangements in human T-cell receptor /+lymphocytes. Eur J Immunol 1989; 19: 1261–5.
Bluestone JA, Crom RQ, Cotterman M, et al. Structure andspecificty of T-cell receptor yon majorhistocompatibility complex antigen specific CD3 + , CD4-, CD8- T lymphocytes. J Exp Med 1988;168: 1899–916.
HaregewoinA, Soman G, Horn RC, Finberg RW. Human y+T cellsrespond to mycobacterial heat-shock protein. Nature 1989; 340: 309–12.
Paliard X, Yssel H, Blanchard D, et al. Antigen specificand MHC non-restricted cytotoxicity of T cell receptor ß+and+ human T-cell clones isolated in IL-4. J Immunol 1989;143: 452–7.
Kozbor D, Trinchieri G, Monos DS, et al. Human TCR-+/+,CD8+ T lymphocytes recognize tetanus toxoid in aMHC restricted fashion. J Exp Med 1989; 169: 1847–51.
Holoshitz J, Koning F, Coligan JE, et al. Isolation ofCD4-, CD8- mycobacteria-reactive T lymphocyte clones from rheumatoid arthritessynovial fluid. Nature 1989; 339: 226–9.
Sturm E, Braakman E, Fisch P, et al. Human V9-V2 TCRlymphocytes show specificity to Daudi Burkitt’s lymphoma cells. J Immunol 1990; 145:3202–8.
Fisch P,Malkovsky M, Braakman E, et al. Gamma/delta T cell clones and natural killercell clones mediate distinct cytolysis. J Exp Med 1990; 171: 1567–79.
Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cellrecognition. Nature 1988; 334:395–402.
Trinchieri G.Biology of Natural Killer Cells. In: Advances in Immunology. New York: AcademicPress, 1989; 187–376.
Seeley JK, Golub SH. Studies on cytotoxity generated in human mixedlymphocyte cultures: 1. TimeCourse and Target spectrum of Several Distinct Concomitant CytotoxicActivities. J Immunol 1978; 120: 1415–22.
Poros A, Klein E.Distinction of Anti-K562 and Anti-AUocytotoxity in in vitro StimulatedPopulations of Human Lymphocytes. Cell Immunol 1979; 46: 57–68.
Masucci MG, KleinE, Argrov S. Disappearance of the NK effect after explantation of lymphocytesand generation of similar nonspecific cytotoxity correlated to the level ofblastogenesis in activated cultures. J Immunol 1980; 124: 2458–63.
Hersey P, Bindon C, Edwards A. Induction of cytotoxic activity in humanlymphocytes against autologous and allogeneic melanoma cells in vitro byculture with interleukin 2. Int J Cancer 1981;28:695–703.
Vose BM, BonnardGD. Specific cytotoxicity against autologous tumour and proliferative responsesof human lymphocytes grown in interleukin 2. Int J Cancer 1982; 29: 33–9.
Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activatedkiller cells phenomenon or lysis of natural killer-resistant freshsolid tumor cells by Interleukin 2-activated autologous human peripheral bloodlymphocytes. J Exp Med 1982; 155: 1823–41.
Bolhuis RLH,Ronteltap CPM. Generation of natural killer (NK) cell activity after mixedlymphocyte culture (MLC): activation of effector cells in NK cell-depleted cellpopulations. Immunol Lett 1980; 1: 191–6.
Bolhuis RLH,Schellekens SH. Induction of natural killer cell activity and allocytotoxicityin human peripheral blood lymphocytes aftermixed lymphocyte culture. Scand J Immunol 1981; 13:401–12.
Van de Griend RJ, Giphart MJ, Van Krimpen BA, Bolhuis RLH. Human T-cellclones exerting multiplecytolytic activities show heterogeneity in susceptibility to inhibition bymonoclonal antibodies. J Immunol 1984; 133: 1222–9.
Clevers H, Alarcon B, Wileman T, Terhorst C. The T Cell Receptor/CD3Complex: A Dynamic ProteinEnsemble. Annu Rev Immunol 1988; 6: 629–62.
Geppert TD, DavisLS, Gur H, et al. Accessory Cell Signals Involved in T-cell Activation. ImmunolRev 1990; 117: 1–66.
Goedegebuure SP,Segal DM, Braakman E, et al. Induction of lysis by TCR y+/CD3+T lymphocytes via CD2 requires triggeringvia the T11, 1 epitope only. J Immunol 1989; 142: 1797–802.
Braakman E, Goedegebuure PS, Vreugdenhil RJ, et al. ICAM melanoma cellsare relatively resistantto CD3 mediated T-cell lysis. Int J Cancer 1990; 46: 475–80.
Pantaleo G, OliveD, Poggi A, et al. Antibody-induced modulation of the CD3/T-cell receptor complex causes T-cell refractoriness byinhibiting the early metabolic steps involved in T-cell activation. JExp Med 1987; 166: 619–24.
Bolhuis RLH,Roozemond RC, Van de Griend RJ. Induction and blocking of cytolysis in CD2+ CD3- NK and CD2+ CD3+cytotoxic T lymphocytes via CD2 50-Kd sheep erythrocyte receptor. JImmunol 1986; 136: 3939–44.
Moingeon P, Chang HC, Wallner BP, et al. CD2-mediated adhesionfacilitates T-Lymphocyte antigenrecognition function. Nature 1989; 339: 312–4.
Van Seventer GA,Shimizu Y, Shaw S. Roles of multiple accessory molecules in T-cell activation.Curr Opin Immunol 1991; 3: 294–303.
Shimizu Y , Shaw S. Lymphocyte interactions with extracellular matrix.Faseb J 1991; 5:2292–9.
Old LJ, Boyse EA. Antigens of tumors and leukemias induced by viruses.Proc Fed 1965; 24: 1009–17.
Srivastava PK,Old LJ. Individually distinct transplantation antigen of chemically inducedmouse tumors. Immunol Today 1988; 9: 78–83.
Hersey P, Meldrum C, Daniels V, et al. Characterization of melanomaantigens recognized by humanT cells. In: Finn OJ, Lotze M, editors. Cellular immunity and the immunotherapyof cancer. New York: Wiley-Liss, 1990: 343–9.
Notter M,Schirrmacher V. Tumor specific T cell clones recognize different proteindeterminants of autologous human melanoma cells. Int J Cancer 1990; 45: 834–41.
Gendler S, Taylor-Papadimitriou J, Duhlig T, et al. A highlyimmunogenic region of a human polymorphic epithelial mucin expressed by carcinomasis made up of tandem repeats. J Biol Chem 1988; 263: 12820–3.
Barnd DL, Lan M, Metzgar R, Finn OJ. Specific, MHC-unrestrictedrecognition of tumor- associatedmucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989; 86: 7159–63.
Jerome KR, Barnd DL, Bendt KM, et al. Cytotoxic T lymphocytes derivedfrom patients with breast adenocarcinoma recognize an epitope present on theprotein core of a mucin molecule preferentially expressed by malignantcells. Cancer Res 1991; 51: 2908–16.
Slovin SF,Lackman RD, Ferrone S, et al. Cellular immune response to human sarcomas:Cytotoxic T cell clones reactive with autologous sarcomas. I. Development,phenotype and specificity. J Immunol 1986; 137: 3042–8.
Crowley NJ,Slingluff CL, Darrow TL, Seigler HF. Generation of human autologousmelanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas.Cancer Res 1990; 50: 492–8.
Tentori L, LongoDL, Zuniga-Pflucker JC, et al. Essential role of the interleukin-2-receptorpathways in thymocyte maturation in vivo. J Exp Med 1988; 168: 1741–8.
Leist TP, Kohler M, Eppler M, Zinkernagel RM. Effects of treatment withIL-2 receptor specific monoclonalantibody in mice: inhibition of cytotoxic T cell responses but not of T help. JImmunol 1989; 143: 628–32.
Biron CA, YoungHA, Kasauan MT. Interleukin-2-induced proliferation of murine natural killercells in vivo. J Exp Med 1990; 171: 173–88.
Chen W, Reese VA, Cheever MA. Adoptively transferred antigen-specific Tcells can be grown andmaintained in large numbers in vivo for extended periods of time byintermittent restimulation with specific antigen plus IL-2. J Immunol 1990;144: 3659–66.
Van de Griend RJ, Ronteltap CPM, Gravekamp C, et al.Interferon ßand recombinant IL-2 can both enhance but by differentpathways, the non-specific cytolytic potential of T3- natural killer cell derivedclones rather than that of T3+ clones. J Immunol 1986; 5: 1700–7.
OettgenHF, Old LJ. The history of cancer immunotherapy. In: DeVita VT, Hellman S,Rosenberg SA, editors. Biologic therapy of cancer. Philadelphia: Lippincott,1991: 87–199.
Nathan C, SpornM. Cytokines in context. J Cell Biol 1991; 981–6.
Rosenberg SA,Lotze MT, Muul LM, et al. Observations on the systemic administration ofautologous lymohokine-activated killer cells and recombinant interleukin-2 topatients with metastatic cancer. N Engl J Med 1985; 313: 1485–92.
Milstein C,Cuello AC. Hybrid hybridomas and their use in immunohistochemistry. Nature1983; 305: 537–40.
LanzavecchiaA, Scheidegger D. The use of hybrid hybridomas to target human cytotoxic Tlymphocytes. Eur J Immunol 1987; 17: 105–11.
TitusJA, Garrido MA, Hecht TT, et al. Human T cells targeted with anti-T3cross-linked to antitumor antibody prevent tumor growth in nude mice. J Immunol1987; 138: 4018–22.
CanevariS, Ménard S, Mezzanzanica D, et al. Anti-ovarian carcinoma anti-T3 heteroconjugates or hybrid antibodies induce tumorcell lysis by cytotoxic T-cells. Int J Cancer 1988; Suppl. 2: 18–21.
Van Dijk J,Tsuruo T, Segal DM, et al. Bispecific antibodies reactive with the multidrug- resistance-related glycoprotein and CD3 inducelysis of multidrug-resistant tumor cells. Int J Cancer 1989; 44: 738–43.
Van Dijk J, Warnaar SO, Van Eendenburg JDH, et al. Induction of Tumor-cell lysis bybi- specific monoclonal antibodiesrecognizing renal-cell carcinoma and CD3 antigen. Int J Cancer 1989;43:344–9.
Van de Griend RJ, Bolhuis RLH, Stoter G, Roozemond RC. Regulation ofcytolytic activity in CD3-and CD3+ killer cell clones by monoclonal antibodies (anti-CD16,anti-CD2, anti-CD3) depends on subclass specificity of target cell IgG-FcR. JImmunol 1987; 138: 3137–44.
Nitta T, Sato K, Yagita H, et al. Preliminary trial of specifictargeting therapy against malignant glioma. Lancet 1990; 335: 368–71.
Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptorchimeric molecules asfunctional receptors with antibody-type specificity. Proc Natl Acad Sci USA1989; 86: 10024–8.
Burg van der MEL, Hoff AM, Lent van M, et al. Carboplatin andcyclophosphamide salvage therapy for ovarian cancer patients relapsing aftercisplatin combination chemotherapy. Eur J Cancer 1991; 27: 248–50.
Mezzanzanica D, Canevari S, Ménard S, et al. Human ovarian carcinomalysis by cytotoxic T cells targeted by bispecific monoclonal antibodies:analysis of the antibody components. Int J Cancer 1988; 41: 609–15.
Pupa SM, Canevari S, Fontanelli R, et al. Activation of mononuclearcells to be used for hybrid monoclonal antibody-inducedlysis of human ovarian carcinoma cells. Int J Cancer 1988; 42: 455–9.
Colnaghi MI,Buraggi GL, Canevari S, et al. Evaluation of the suitability of a monoclonal antibody raised against human ovarian carcinomafor therapeutic approaches. Nucl Med Biol 1989; 16:633–6.
Cameron RB,Mclntosh JK, Rosenberg SA. Synergistic antitumor effects of combinationimmunotherapy with recombinant hybrid alpha-interferon in the treatment ofestablished murine hepatic metastases. Cancer Res 1988; 48: 5810–7.
Rosenberg SA,Schwartz S, Spiess PJ. Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2,alpha-interferon, and tumor-infiltrating lymphocytes. J Natl Cancer Inst1988; 80: 1393–7.
Negrier S, Philip T, Stoter G, et al. Interleukin-2 with or without LAKcells in metastatic renal cell carcinoma: A report of a European multicentrestudy. Eur J Cancer Clin Oncol 1989; 25: S21–S8.
Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use ofhigh-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210: 474–85.
Abrams JS, RaynerAA, Wiernik PH, et al. High-dose recombinant interleukin-2 alone: A regimen with limited activity in the treatment ofadvanced renal cell carcinoma. J Natl Cancer Inst 1990; 82: 1202–6.
Fisher RI, Coltman CA, Doroshow JH, et al. Metastatic renal cancertreated with interleukin-2 and lymphokine-activated killer cells. Ann Int Med1988; 108: 518–23.
Parkinson DR, Fisher RI, Rayner AA, et al. Therapy of renal cellcarcinoma with interleukin-2 and lymphokine-activatedkiller cells: Phase II experience with a hybrid bolus and continuous infusioninterleukin-2 regimen. J Clin Oncol 1990; 8: 1630–6.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Bolhuis, R.L.H., Stoter, G. (1993). Interleukin-2, lymphocytes and monoclonal antibodies. In: Wagstaff, J. (eds) The role of interleukin-2 in the treatment of cancer patients. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-1753-1_8
Download citation
DOI: https://doi.org/10.1007/978-94-011-1753-1_8
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-4769-2
Online ISBN: 978-94-011-1753-1
eBook Packages: Springer Book Archive